Clinical Trials Logo

Infection clinical trials

View clinical trials related to Infection.

Filter by:

NCT ID: NCT02789371 Recruiting - Inflammation Clinical Trials

Comparing of Modified Wet Suction Technique and Dry Suction Technique for EUS-FNA of Solid Occupying Lesions

Start date: May 2016
Phase: N/A
Study type: Interventional

The purpose of this study is to compare the diagnosis accuracy of modified wet suction technique and 5ml dry suction technique on solid occupying lesions.

NCT ID: NCT02788942 Completed - Wound Infection Clinical Trials

The Removing Port of the Laparoscopic Cholecystectomy Material

Start date: March 2016
Phase: N/A
Study type: Interventional

Laparoscopic cholecystectomy is gold standard for gallstones. In this study the investigators are investigating the effect of the removing of cholecystectomy material from different ports, to the port site infections.

NCT ID: NCT02787603 Completed - Heart Failure Clinical Trials

Procalcitonin in Early Antibiotic Interruption in Patient With Bacterial Pulmonary infeCtion and Acute Heart Failure

EPICAD
Start date: January 2015
Phase: N/A
Study type: Interventional

Introduction: Acute Heart Failure is frequently decompensated by pulmonary infection, but the diagnosis of pulmonary infection sometimes is difficult in these patients due to similar signals and clinical symptoms in both pathologies. Furthermore, when it is possible the diagnosis of pulmonary infection, physicians may have difficult to determine etiology and delaying antibiotic therapy. Procalcitonin (PCT) have been used like a biomarker to determine the period of use of antibiotics in patients with acute respiratory infections. It is specific for bacterial infections and it have showed as a marker of severity infection and may help to determine interruption period of antibiotic therapy in a safety way for the patient. Aim: Evaluate levels of PCT related to interruption of antibiotics in patients with decompensated acute heart failure (DAHF) with suspected bacterial pulmonary infection. Methods: In this pilot project will be included around 100 patients, randomized in two groups: group A (PCT levels may guide the interruption of antibiotic at day 5) or group B (antibiotic period will be determined by the physician without the knowledge of PCT levels). Will be collected laboratorial and clinical data at days 0,3 and 5. Both groups will be compared to evaluate PCT levels and total period of antibiotic therapy, hospitalization and readmission in 30 days. This study will determine the sensibility/specificity of PCT in patients with DAHF.

NCT ID: NCT02786381 Completed - Clinical trials for Respiratory Tract Infections

Idylla IFV-RSV Panel Clinical Testing

RP1
Start date: November 2015
Phase: N/A
Study type: Observational

This clinical study will collect fresh samples and perform laboratory testing on fresh and archived samples as described in the protocol.

NCT ID: NCT02784002 Completed - Clinical trials for Clostridium Difficile Infection

A Study of Ridinilazole (SMT19969) Compared With Fidaxomicin for the Treatment of Clostridium Difficile Infection (CDI)

Start date: December 2014
Phase: Phase 2
Study type: Interventional

The purpose of this research study is to evaluate the safety and effectiveness of Ridinilazole (SMT19969) in treating C. difficile Infection (CDI).

NCT ID: NCT02783976 Completed - HCV Infection Clinical Trials

Sovaldi-based Regimens in Patients in Mexico With Chronic Hepatitis C Virus Infection in Clinical Practice

Start date: October 28, 2016
Phase:
Study type: Observational

This study will collect and evaluate information on the safety and efficacy of Sovaldi-based regimens in routine clinical practice in Mexico. The primary objective of this study is to assess the rates of serious adverse events/reactions (SAEs/SADRs) and adverse events/reactions (AEs/ADRs) in adult participants with chronic hepatitis C virus (HCV) infection treated with Sovaldi in routine clinical practice.

NCT ID: NCT02782988 Completed - Clinical trials for Congenital Cytomegalovirus Infection

Assesment of Olfactory Disorders and Performance of a New Olfactory Test in Children With Congenital CMV

INFECSMELL
Start date: May 2016
Phase:
Study type: Observational

CMV lesions were found in the olfactory system of children with congenital CMV infection but no study has hitherto examined the impact of congenital CMV infection on olfaction. So the investigators propose in this study to assess the proportion of children with olfactory deficits among children with congenital CMV infection. Second this study will also evaluate performances of a new olfactory test, based on discrimination of binary odorant mixtures.

NCT ID: NCT02782078 Completed - Clinical trials for Staphylococcal Infections

Pharmacological Interaction of Rifampicin on Clindamycin in Staphylococcic Osteoarticular Infections

DALARI
Start date: March 6, 2017
Phase: N/A
Study type: Interventional

Clindamycin and rifampicin are authorized in osteoarticular infection treatment (IDSA guidelines) but some interaction is observed. The objective of this study is to evaluate and quantify rifampicin interaction on clindamycin

NCT ID: NCT02781571 Completed - Clinical trials for Hepatitis C Virus Infection

Sofosbuvir/Velpatasvir Fixed Dose Combination in Participants With Chronic Hepatitis C Virus Infection Who Have Received a Liver Transplant

Start date: July 27, 2016
Phase: Phase 2
Study type: Interventional

The primary objectives of this study are to evaluate the efficacy, safety, and tolerability of sofosbuvir /velpatasvir (SOF/VEL) fixed-dose combination (FDC) in participants with chronic hepatitis C virus (HCV) who have received a liver transplant.

NCT ID: NCT02781558 Completed - Clinical trials for Hepatitis C Virus Infection

Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed-Dose Combination (FDC) and Sofosbuvir/Velpatasvir FDC and Ribavirin in Participants With Chronic Genotype 3 HCV Infection and Cirrhosis

Start date: July 29, 2016
Phase: Phase 2
Study type: Interventional

The primary objectives of this study are to evaluate the efficacy, safety, and tolerability of sofosbuvir/velpatasvir (SOF/VEL) fixed-dose combination (FDC) and SOF/VEL FDC and ribavirin (RBV) for 12 weeks in participants with chronic genotype 3 hepatitis C virus (HCV) infection and compensated cirrhosis.